Evidence map›Paper›PMID 42882924›Full record

ArticleCancers2026

Contemporary Clinical Outcomes and Healthcare Utilization in Older Adults with Acute Myeloid Leukemia: Insights from a Single-Center Retrospective Cohort.

Tina Y Zhang, Alex Y Ge, Shyam A Patel, Poorva Bindal, Jan Cerny, Andrew Gillis-Smith, Muthalagu Ramanathan, Sakiko Suzuki, Laurie Pearson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tina Y ZhangDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Alex Y GeDepartment of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Shyam A PatelDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.ORCID 0000-0002-8208-1902
Poorva BindalDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.ORCID 0000-0002-6602-5505
Andrew Gillis-SmithDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Muthalagu RamanathanDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.
Sakiko SuzukiDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.ORCID 0009-0005-5452-6096
Laurie PearsonDivision of Hematology/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) predominantly affects older adults; however, patients 75 years of age and older are often not candidates for curative-intent treatments. Data on their treatment patterns, survival outcomes, and healthcare utilization are limited, and we evaluated these outcomes among patients 75 years of age and older with AML.

methodsWe retrospectively analyzed 97 patients aged 75 years and older managed at our academic safety-net hospital between 2016 and 2025.

resultsMedian overall survival (mOS) was 95 days for all patients. Receipt of any AML-directed therapy was associated with longer mOS compared with no leukemia-directed treatment (144 days, 95% CI: 98-184 vs. 17 days, 95% CI: 7-50;

conclusionsOur findings highlight real-world challenges for older adults with AML, including the need for more effective treatments for patients with

Indexed as

acute myeloid leukemiaclinical outcomeshealthcare utilizationolder patients

Identifiers

PMID42882924
PMCPMC13664294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.